Clinical Trials
23 trialsIMPACT
University of Utah
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
ADAPT-HEM
Beijing Biotech
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
The First Hospital of Jilin University
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
CARE-Heme
University of Alabama at Birmingham
EMN36
European Myeloma Network B.V.
UltraFrailMM
University of Utah
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Institute of Hematology & Blood Diseases Hospital, China
CAREMM-004
Institute of Hematology & Blood Diseases Hospital, China
CAREMM-002
Institute of Hematology & Blood Diseases Hospital, China
A Study of CT0596 in Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Anhui Provincial Hospital
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Tongji Hospital
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd.
NIMMS
St. Olavs Hospital
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Hrain Biotechnology Co., Ltd.
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Peking University First Hospital